Hepcidin

"HAMP" redirects here. For other uses, see HAMP (disambiguation).

Hepcidin is a protein that in humans is encoded by the HAMP gene. Hepcidin is a key regulator of the entry of iron into the circulation in mammals.^[4]

HAMP
Available structures PDB Human UniProt search: PDBe RCSB List of PDB id codes 1M4E, 1M4F, 2KEF, 3H0T, 4QAE
Identifiers
Aliases	HAMP, HEPC, HFE2B, LEAP1, PLTR, hepcidin antimicrobial peptide
External IDs	OMIM: 606464 HomoloGene: 81623 GeneCards: HAMP
Gene location (Human) Chr. Chromosome 19 (human)^[1] Band 19q13.12 Start 35,280,716 bp^[1] End 35,285,143 bp^[1]
RNA expression pattern Bgee Human Mouse (ortholog) Top expressed in right lobe of liver optic nerve caput epididymis body of pancreas pancreatic ductal cell internal globus pallidus substantia nigra hypothalamus vena cava amygdala n/a More reference expression data BioGPS More reference expression data
Gene ontology Molecular function hormone activity iron ion transmembrane transporter inhibitor activity signaling receptor binding Cellular component cytoplasm extracellular region apical cortex intercalated disc extracellular space Biological process negative regulation of iron export across plasma membrane negative regulation of intestinal absorption positive regulation of receptor internalization negative regulation of transcription by RNA polymerase II negative regulation of iron ion transmembrane transporter activity response to iron ion multicellular organismal iron ion homeostasis defense response to bacterium immune response positive regulation of receptor catabolic process positive regulation of protein polyubiquitination negative regulation of ion transmembrane transporter activity cellular iron ion homeostasis cellular response to lipopolysaccharide human ageing cellular response to tumor necrosis factor liver regeneration cellular response to bile acid cellular response to interleukin-6 response to iron ion starvation response to vitamin A response to erythropoietin positive regulation of cell growth involved in cardiac muscle cell development response to ethanol acute-phase response cellular response to X-ray response to zinc ion negative regulation of iron ion transmembrane transport antimicrobial humoral immune response mediated by antimicrobial peptide killing of cells of other organism defense response to fungus regulation of signaling receptor activity signal transduction Sources:Amigo / QuickGO
Orthologs Species Human Mouse Entrez 57817 n/a Ensembl ENSG00000105697 n/a UniProt P81172 n/a RefSeq (mRNA) NM_021175 n/a RefSeq (protein) NP_066998 n/a Location (UCSC) Chr 19: 35.28 – 35.29 Mb n/a PubMed search ^[2] n/a
Wikidata
View/Edit Human

Hepcidin
Solution structure of hepcidin-25.^[3]
Identifiers
Symbol	Hepcidin
Pfam	PF06446
InterPro	IPR010500
SCOP2	1m4f / SCOPe / SUPFAM
OPM superfamily	153
OPM protein	1m4e
Available protein structures: Pfam   structures / ECOD   PDB RCSB PDB; PDBe; PDBj PDBsum structure summary

hepcidin antimicrobial peptide
Identifiers
Symbol	HAMP
NCBI gene	57817
HGNC	15598
OMIM	606464
RefSeq	NM_021175
UniProt	P81172
Other data
Locus	Chr. 19 q13.1
Search for Structures Swiss-model Domains InterPro

During conditions in which the hepcidin level is abnormally high, such as inflammation, serum iron falls due to iron trapping within macrophages and liver cells and decreased gut iron absorption. This typically leads to anemia due to an inadequate amount of serum iron being available for developing red blood cells. When the hepcidin level is abnormally low such as in hemochromatosis, iron overload occurs due to increased ferroportin mediated iron efflux from storage and increased gut iron absorption.

Structure

Hepcidin exists as a preprohormone (84 amino acids), prohormone (60 amino acids), and hormone (25 amino acids). Twenty- and 22-amino acid metabolites of hepcidin also exist in the urine. Deletion of 5 N-terminal amino acids results in loss of function. The conversion of prohepcidin to hepcidin is mediated by the prohormone convertase furin.^[5] This conversion may be regulated by alpha-1 antitrypsin.^[6]

Hepcidin is a tightly folded polypeptide with 32% beta sheet character and a hairpin structure stabilized by 4 disulfide bonds. The structure of hepcidin has been determined through solution NMR.^[3] NMR studies showed a new model for hepcidin: at ambient temperatures, the protein interconverts between two conformations, which could be individually resolved by temperature variation. The solution structure of hepcidin was determined at 325 K and 253 K in supercooled water. X-ray analysis of a co-crystal with Fab revealed a structure similar to the high-temperature NMR structure.^[7]

Function

Further information: Human iron metabolism

 

Diagram showing how hepcidin controls ferroportin (FPN) levels which in turn control entry of iron into the circulation

Hepcidin is a regulator of iron metabolism. It inhibits iron transport by binding to the iron export channel ferroportin which is located in the basolateral plasma membrane of gut enterocytes and the plasma membrane of reticuloendothelial cells (macrophages), ultimately resulting in ferroportin breakdown in lysosomes.^[8][9] It has been shown that hepcidin is able to bind to the central cavity of ferroportin, thus occluding iron export from the cell. This suggests that hepcidin is able to regulate iron export independently of ferroportin endocytosis and ubiquitination, and is thus quickly inducible and reversible.^[10][11] In enterocytes, this prevents iron transmission into the hepatic portal system, thereby reducing dietary iron absorption. In macrophages, ferroportin inhibition causes iron sequestration within the cell. Increased hepcidin activity is partially responsible for reduced iron availability seen in anemia of chronic inflammation, such as kidney failure and that may explain why patient with end stage renal failure may not respond to oral iron replacement.^[12]

Any one of several mutations in hepcidin result in juvenile hemochromatosis. The majority of juvenile hemochromatosis cases are due to mutations in hemojuvelin.^[13] Mutations in TMPRSS6 can cause anemia through dysregulation of hepcidin.^[14]

Hepcidin has strong antimicrobial activity against Escherichia coli strain ML35P and Neisseria cinerea and weaker antimicrobial activity against Staphylococcus epidermidis, Staphylococcus aureus and Streptococcus agalactiae. It is also active against the fungus Candida albicans, but has no activity against Pseudomonas aeruginosa.^[15]

Regulation

Hepcidin synthesis and secretion by the liver is controlled by iron stores, inflammation (hepcidin is an acute phase reactant), hypoxia, and erythropoiesis.^[16] In response to large iron stores, production of Bone Morphogenic Protein (BMP) is induced, which binds to receptors on hepatocytes and induces hepcidin expression via the SMAD pathway.^[17] Inflammation causes an increase in hepcidin production by releasing the signaling molecule interleukin-6 (IL-6), which binds to a receptor and upregulates the HAMP gene via the JAK/STAT pathway.^[17] Hypoxia negatively regulates hepcidin production via production the transcription factor hypoxia-inducible factor (HIF), which under normal conditions is degraded by von Hippel-Lindau (VHL) and prolyl dehydrogenase (PHD). When hypoxia is induced, however, PHD is inactivated, thus allowing HIF to down-regulate hepcidin production. Erythropoiesis decreases hepcidin production via production of erythropoietin (EPO), which has been shown to down-regulate hepcidin production.^[17]

Severe anaemia is associated with low hepcidin levels, even in the presence of inflammation.^[18] Erythroferrone, produced in erythroblasts, has been identified as inhibiting hepcidin and so providing more iron for hemoglobin synthesis in situations such as stress erythropoiesis.^[19][20]

Vitamin D has been shown to decrease hepcidin, in cell models looking at transcription and when given in large doses to human volunteers. Optimal function of hepcidin may be predicated upon the adequate presence of vitamin D in the blood.^[21]

History

The peptide was initially reported in January 1998 by Valore,E., Park,C. and Ganz,T. in the SWISS-PROT database as entry P81172 and named hepcidin^[15] after it was observed that it was produced in the liver ("hep-") and appeared to have bactericidal properties ("-cide" for "killing"). Detailed descriptions were published in 2000-2001.^[22][23][24] Although it is primarily synthesized in the liver, smaller amounts are synthesised in other tissues such as fat cells.^[25]

Hepcidin was first discovered in human urine and serum^[26] Soon after this discovery, researchers discovered that hepcidin production in mice increases in conditions of iron overload as well as in inflammation. Genetically modified mice engineered to overexpress hepcidin died shortly after birth with severe iron deficiency, again suggesting a central and not redundant role in iron regulation. The first evidence that linked hepcidin to the clinical condition known as the anemia of inflammation came from the lab of Nancy Andrews in Boston when researchers looked at tissue from two patients with liver tumors with a severe microcytic anemia that did not respond to iron supplements. The tumor tissue appeared to be overproducing hepcidin, and contained large quantities of hepcidin mRNA. Removing the tumors surgically cured the anemia.^{[citation needed]}

 

Hepcidin (blue) bound to the central cavity of ferroportin (FPN)

Taken together, these discoveries suggested that hepcidin regulates the absorption of iron into the body.

Clinical significance

There are many diseases where failure to adequately absorb iron contributes to iron deficiency and iron deficiency anaemia. The treatment will depend on the hepcidin levels that are present, as oral treatment will be unlikely to be effective if hepcidin is blocking enteral absorption, in which cases parenteral iron treatment would be appropriate. Studies have found that measuring hepcidin would be of benefit to establish optimal treatment,^[27] although as this is not widely available, C-reactive protein (CRP) is used as a surrogate marker.

β-thalassemia, one of the most common congenital anemias, arises from partial or complete lack of β-globin synthesis. Excessive iron absorption is one of the main features of β-thalassemia and can lead to severe morbidity and mortality. The serial analyses of β-thalassemic mice indicate hemoglobin levels decreases over time, while the concentration of iron in the liver, spleen, and kidneys markedly increases. The overload of iron is associated with low levels of hepcidin. Patients with β-thalassemia also have low hepcidin levels. The observations led researchers to hypothesize that more iron is absorbed in β-thalassemia than is required for erythropoiesis. Increasing expression of hepcidin in β-thalassemic mice limits iron overload, and also decreases formation of insoluble membrane-bound globins and reactive oxygen species, and improves anemia.^[28] Mice with increased hepcidin expression also demonstrated an increase in the lifespan of their red cells, reversal of ineffective erythropoiesis and splenomegaly, and an increase in total hemoglobin levels. From these data, researchers suggested that therapeutics to increase hepcidin levels or act as hepcidin agonists could help treat the abnormal iron absorption in individuals with β-thalassemia and related disorders.^[29] In later studies in mice,^[30] erythroferrone has been suggested to be the factor that is responsible for the hepcidin suppression. Correcting hepcidin and iron levels in these mice did not improve their anemia.^[30]

References

1. GRCh38: Ensembl release 89: ENSG00000105697 – Ensembl, May 2017
2. "Human PubMed Reference:". National Center for Biotechnology Information, U.S. National Library of Medicine.
3. PDB: 1M4F​; Hunter HN, Fulton DB, Ganz T, Vogel HJ (October 2002). "The solution structure of human hepcidin, a peptide hormone with antimicrobial activity that is involved in iron uptake and hereditary hemochromatosis". The Journal of Biological Chemistry. 277 (40): 37597–37603. doi:10.1074/jbc.M205305200. PMID 12138110.
4. Ganz T (August 2003). "Hepcidin, a key regulator of iron metabolism and mediator of anemia of inflammation". Blood. 102 (3): 783–788. doi:10.1182/blood-2003-03-0672. PMID 12663437.
5. Valore EV, Ganz T (2008). "Posttranslational processing of hepcidin in human hepatocytes is mediated by the prohormone convertase furin". Blood Cells, Molecules & Diseases. 40 (1): 132–138. doi:10.1016/j.bcmd.2007.07.009. PMC 2211381. PMID 17905609.
6. Pandur E, Nagy J, Poór VS, Sarnyai A, Huszár A, Miseta A, Sipos K (April 2009). "Alpha-1 antitrypsin binds preprohepcidin intracellularly and prohepcidin in the serum". The FEBS Journal. 276 (7): 2012–2021. doi:10.1111/j.1742-4658.2009.06937.x. PMID 19292870. S2CID 28974553.
7. PDB: 3H0T​; Jordan JB, Poppe L, Haniu M, Arvedson T, Syed R, Li V, et al. (September 2009). "Hepcidin revisited, disulfide connectivity, dynamics, and structure". The Journal of Biological Chemistry. 284 (36): 24155–24167. doi:10.1074/jbc.M109.017764. PMC 2782009. PMID 19553669.
8. Rossi E (August 2005). "Hepcidin--the iron regulatory hormone". The Clinical Biochemist. Reviews. 26 (3): 47–49. PMC 1240030. PMID 16450011.
9. Gulec S, Anderson GJ, Collins JF (August 2014). "Mechanistic and regulatory aspects of intestinal iron absorption". American Journal of Physiology. Gastrointestinal and Liver Physiology. 307 (4): G397–G409. doi:10.1152/ajpgi.00348.2013. PMC 4137115. PMID 24994858.
10. Aschemeyer S, Qiao B, Stefanova D, Valore EV, Sek AC, Ruwe TA, et al. (February 2018). "Structure-function analysis of ferroportin defines the binding site and an alternative mechanism of action of hepcidin". Blood. 131 (8): 899–910. doi:10.1182/blood-2017-05-786590. PMC 5824336. PMID 29237594.
11. Nemeth E, Ganz T (June 2021). "Hepcidin-Ferroportin Interaction Controls Systemic Iron Homeostasis". International Journal of Molecular Sciences. 22 (12): 6493. doi:10.3390/ijms22126493. PMC 8235187. PMID 34204327.
12. Ashby DR, Gale DP, Busbridge M, Murphy KG, Duncan ND, Cairns TD, et al. (May 2009). "Plasma hepcidin levels are elevated but responsive to erythropoietin therapy in renal disease". Kidney International. 75 (9): 976–981. doi:10.1038/ki.2009.21. PMID 19212416.
13. Core AB, Canali S, Babitt JL (2014). "Hemojuvelin and bone morphogenetic protein (BMP) signaling in iron homeostasis". Frontiers in Pharmacology. 5: 104. doi:10.3389/fphar.2014.00104. PMC 4026703. PMID 24860505.
14. Iron-Deficiency Anemia: New Insights for the Healthcare Professional: 2011 Edition. Scholarly Media LLC. Dec 2012. ISBN 978-1-4649-8960-5.
15. "Hepcidin P81172". UniProt. December 15, 1998.
16. Zhao N, Zhang AS, Enns CA (June 2013). "Iron regulation by hepcidin". The Journal of Clinical Investigation. 123 (6): 2337–2343. doi:10.1172/JCI67225. PMC 3668831. PMID 23722909.
17. Rishi G, Wallace DF, Subramaniam VN (March 2015). "Hepcidin: regulation of the master iron regulator". Bioscience Reports. 35 (3). doi:10.1042/bsr20150014. PMC 4438303. PMID 26182354.
18. Abuga KM, Muriuki JM, Uyoga SM, Mwai K, Makale J, Mogire RM, et al. (July 2022). "Hepcidin regulation in Kenyan children with severe malaria and non-typhoidal Salmonella bacteremia". Haematologica. 107 (7): 1589–1598. doi:10.3324/haematol.2021.279316. PMC 9244826. PMID 34498446. S2CID 237454351.
19. Koury MJ. . The Hematologist. American Society of Hematology. Archived from the original on 28 January 2019. Retrieved 26 August 2015.
20. Kautz L, Jung G, Valore EV, Rivella S, Nemeth E, Ganz T (July 2014). "Identification of erythroferrone as an erythroid regulator of iron metabolism". Nature Genetics. 46 (7): 678–684. doi:10.1038/ng.2996. PMC 4104984. PMID 24880340.
21. Bacchetta J, Zaritsky JJ, Sea JL, Chun RF, Lisse TS, Zavala K, et al. (March 2014). "Suppression of iron-regulatory hepcidin by vitamin D". Journal of the American Society of Nephrology. 25 (3): 564–572. doi:10.1681/ASN.2013040355. PMC 3935584. PMID 24204002.
22. Krause A, Neitz S, Mägert HJ, Schulz A, Forssmann WG, Schulz-Knappe P, Adermann K (September 2000). "LEAP-1, a novel highly disulfide-bonded human peptide, exhibits antimicrobial activity". FEBS Letters. 480 (2–3): 147–150. doi:10.1016/S0014-5793(00)01920-7. PMID 11034317. S2CID 9161764.
23. Pigeon C, Ilyin G, Courselaud B, Leroyer P, Turlin B, Brissot P, Loréal O (March 2001). "A new mouse liver-specific gene, encoding a protein homologous to human antimicrobial peptide hepcidin, is overexpressed during iron overload". The Journal of Biological Chemistry. 276 (11): 7811–7819. doi:10.1074/jbc.M008923200. PMID 11113132.
24. Park CH, Valore EV, Waring AJ, Ganz T (March 2001). "Hepcidin, a urinary antimicrobial peptide synthesized in the liver". The Journal of Biological Chemistry. 276 (11): 7806–7810. doi:10.1074/jbc.M008922200. PMID 11113131.
25. Bekri S, Gual P, Anty R, Luciani N, Dahman M, Ramesh B, et al. (September 2006). "Increased adipose tissue expression of hepcidin in severe obesity is independent from diabetes and NASH". Gastroenterology. 131 (3): 788–796. doi:10.1053/j.gastro.2006.07.007. PMID 16952548.
26. Kemna EH, Tjalsma H, Willems HL, Swinkels DW (January 2008). "Hepcidin: from discovery to differential diagnosis". Haematologica. 93 (1): 90–97. doi:10.3324/haematol.11705. hdl:2066/70062. PMID 18166790.
27. Bregman DB, Morris D, Koch TA, He A, Goodnough LT (February 2013). "Hepcidin levels predict nonresponsiveness to oral iron therapy in patients with iron deficiency anemia". American Journal of Hematology. 88 (2): 97–101. doi:10.1002/ajh.23354. PMID 23335357. S2CID 42656065.
28. Gardenghi S, Ramos P, Marongiu MF, Melchiori L, Breda L, Guy E, et al. (December 2010). "Hepcidin as a therapeutic tool to limit iron overload and improve anemia in β-thalassemic mice". The Journal of Clinical Investigation. 120 (12): 4466–4477. doi:10.1172/JCI41717. PMC 2993583. PMID 21099112.
29. Kroot JJ, Tjalsma H, Fleming RE, Swinkels DW (December 2011). "Hepcidin in human iron disorders: diagnostic implications". Clinical Chemistry. 57 (12): 1650–1669. doi:10.1373/clinchem.2009.140053. hdl:2066/97956. PMID 21989113.
30. Moura IC, Hermine O (October 2015). "Erythroferrone: the missing link in β-thalassemia?". Blood. 126 (17): 1974–1975. doi:10.1182/blood-2015-09-665596. PMID 26494918.

Further reading

• Camaschella C (December 2005). "Understanding iron homeostasis through genetic analysis of hemochromatosis and related disorders". Blood. 106 (12): 3710–3717. doi:10.1182/blood-2005-05-1857. PMID 16030190.

External links

• hepcidin at the U.S. National Library of Medicine Medical Subject Headings (MeSH)
• Intrinsic LifeSciences - Hepcidin Research Facility, The BioIron Company
• Hepcidinanalysis.com - Service for Hepcidin measurements: Scientific Research, Patients and Clinical Trials
• Protein Data Bank Page
• peptide shop
• PDBe-KB provides an overview of all the structure information available in the PDB for Human Hepcidin